Actualites therapeutiques 2002 (1).

Scheen, André

Download

Article (Scientific journals)

Actualites therapeutiques 2002 (1).

Scheen, André

2002 • In Revue Médicale de Liège, 57 (11), p. 719-31

Peer reviewed

Permalink
https://hdl.handle.net/2268/10590

PubMed
12564104

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

200211_08.pdf

Publisher postprint (514.54 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Belgium; Drug Therapy/trends; Evidence-Based Medicine; Humans; Internal Medicine/trends; Randomized Controlled Trials as Topic

Abstract :

[en] The most important drugs registered and/or launched in Belgium during the last year in the various disciplines of internal medicine will be briefly described. The main characteristics of each molecule and its modalities of appropriate use in clinical practice will be emphasized. For all these molecules, both the efficacy and tolerance have been proven in randomised clinical trials according to the rules of Evidence-Based Medicine.

Disciplines :

Pharmacy, pharmacology & toxicology

Author, co-author :

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale

Language :

French

Title :

Actualites therapeutiques 2002 (1).

Alternative titles :

[en] Therapeutic advances in 2002 (1)

Publication date :

2002

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

719-31

Peer reviewed :

Peer reviewed

Additional URL :

http://www.rmlg.ulg.ac.be

Available on ORBi :

since 08 April 2009

Statistics

Number of views

314 (0 by ULiège)

Number of downloads

1263 (5 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Scheen AJ.- Actualités thérapeutiques 2000. Rev Med Liège, 2000, 55, 852-861.
Scheen AJ.- Actualités thérapeutiques 2001. Rev Med Liège, 2001, 56, 612-624.
Scheen AJ.- Le médicament du mois. Le nébivolol (Nobiten®). Rev Med Liège, 2001, 56, 788-791.
Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators.- Single-bolus tenecteplase compared with front-loaded altepase in acute myocardial infarction: The ASSENT-2 double-blind randomised trial. Lancet, 1999, 354, 716-722.
Piérard L.- Effets du valsartan dans l'insuffisance cardiaque chronique: L'étude Val-HeFT. Rev Med Liège, 2002, 57, 57-59.
Weekers L, Krzesinski J-M.- Rôle néphroprotecteur des antagonistes du récepteur de l'angiotensine II (ARA) dans le diabète de type 2: résultats des études IDNT et RENAAL. Rev Med Liège, 2001, 56, 723-726.
Bartsch P.- Traitement de l'asthme et recommandations internationales. Rev Med Liège, 2000, 55, 325-331.
Geha RS, Meltzer EO.- Desloratadine: A new, nonse-dating, oral antihistamine. J Allergy Clin Immunol, 2001, 107, 751-762.
Louis E.- Le médicament du mois. Le rabéprazole (Pariet®). Rev Med Liège, 2002, 57, 53-56.
Hovinga CA.- Levetiracetam: A novel antiepileptic drug. Pharmacotherapy, 2001, 21, 1375-1388.
Goren JL, Levin GM.- Quetiapine, an atypical antipsychotic. Pharmacotherapy, 1998, 18, 1183-1194.
Weinstock M.- Selectivity of cholinesterase inhibition. Clinical implications for the treatment of Alzheimer's disease. CNS Drugs, 1999, 12, 307-323.
Andrianne R.- Le médicament du mois. Le sildénafil (Viagra®). Rev Med Liège, 1999, 54, 58-61.
Wagner G, Wyllie MG (Eds).- Apomorphine SL: A new era in the management of erectile dysfunction. Int J Impotence Res, 2001, 13 (Suppl 3), S1-S51.
Blondeau JM, Hansen GT.- Moxifloxacin: A review of the microbiological, pharmacological, clinical and safety features. Exp Opin Pharmacother, 2001, 2, 317-335.
Scheen AJ.- Le médicament du mois. La lévofloxacine (Tavanic®). Rev Med Liège, 2000, 55, 1015-1017.
Keating GM, Jarvis B.- Caspofungin. Drugs, 2001, 61, 1121-1129.
MacLennan JM, Shackley F, Heath PT et al.- Safety, immunogenicity and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants. A randomized controlled trial. JAMA, 2000, 283, 2795-2801.
Lepage Ph.- Le médicament du mois. Le Meningitec®. Rev Med Liège, 2001, 56, 124-125.
Nkoghe D, Léonard P, Nnegue S, et al.- Prise en charge des patients infectés par le VIH. Expérience du CHU de Liège. Rev Med Liège, 2002, 57, 546-551.
Sham HL, Kempf DJ, Molla A, et al.- ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother, 1998, 42, 3218-3224.
Kulbertus H, Scheen AJ.- L'étude clinique du mois. La "Heart Protection Study" MRC/BHF. Rev Med Liège, 2002, 57, 613-616.
Teo KK, Burton JR.- Who should receive HMG CoA reductase inhibitors? Drugs, 2002, 62, 1707-1715.
EUROASPIRE II Study Group.- Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J, 2001, 22, 554-572.
Scheen AJ.- De l'inapplicabilité de certaines recommandations thérapeutiques en pratique: L'exemple du remboursement des médicaments hypolipidémiants en Belgique. Rev Med Liège, 2000, 55, 260-264.
Scheen AJ.- Le médicament du mois. La fluvastatine (Lescol®). Rev Med Liège, 1997, 52, 442-444.
Scheen AJ.- L'étude LIPS: Prévention par la fluvastatine des accidents cardiaques après angioplastie coronaire percutanée. Rev Med Liège, 2002, 57, 479-484.
Wagstaff AJ, Goa KL.- Rosiglitazone. A review of its use in the management of type 2 diabetes mellitus. Drugs, 2002, 62, 1805-1837.
Scheen AJ.- Le médicament du mois. La rosiglitazone (Avandia®). Rev Med Liège, 2002, 57, 236-239.
Gillies PS, Dunn CJ.- Pioglitazone. Drugs, 2000, 60, 333-343.
Gaspard U, Van den Brûle F, Pintiaux A, Foidart JM.-Balance bénéfice/risque du traitement oestroprogestatif postménopausique en péril dans l'étude Women's Health Initiative: Attitude pratique du clinicien. Rev Med Liège, 2002, 57, 556-562.
Gaspard U.- Le médicament du mois. Totelle Cycle®: Nouvelle association séquentielle oestroprogestative pour l'hormonothérapie substitutive de la ménopause. Rev Med Liège, 2002, 57, 408-412.
Sitruk-Ware R.- Progestogens in hormonal replacement therapy: New molecules, risks and benefits. Menopause, 2002, 9, 6-15.
Scheen AJ.- Le médicament du mois. Le rofécoxib (Vioxx®). Rev Med Liège, 2000, 55, 751-753.
Scheen AJ.- Le médicament du mois. Le célécoxib (Celebrex®). Rev Med Liège, 2001, 56, 53-55.
Reuben SS, Fingeroth R, Krushell R, Maciolek H.- Evaluation of the safety and efficacy of the perioperative administration of rofecoxib for total knee arthroplasty. J Arthroplasty, 2002, 17, 26-31.
Reginster JY- Les bisphosphonates. Rev Med Liège, 1996, 51, 120-122.
Scheen AJ.- Le médicament du mois. L'alendronate (Fosamax®). Rev Med Liège, 1998, 53, 220-222.
Sharpe M, Noble S, Spencer CM.- Alendronate. An update of its use in osteoporosis. Drugs, 2001, 61, 999-1039.
McClung MR, Geusens P, Miller PD et al.- Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med, 2001, 344, 333-340.
Berenson JR, Vescio R, Henick K, et al.- A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease. Cancer, 2001, 91, 144-154.
Kaiser MJ, Malaise MG.- Comment je traite ... une polyarthrite rhumatoïde. L'avènement d'une nouvelle ère thérapeutique: Les anticorps anti-TNF-α. Rev Med Liège, 2002, 57, 486-492.
Goldman JM, Melo JV.- Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia (Editorial). N Engl J Med, 2001, 344, 1084-1086.
Druker BJ, Talpaz M, Resta DJ, et al.- Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med, 2001, 344, 1031-1037.
Humblet-Baron S, Baron F, Pirson L, et al.- Traitement moléculaire du cancer: Le ST1571, un inhibiteur des tyrosines kinases. Med Hyg, 2002, 60, 1504-1508.